| Document |
Document Title |
|
JP2003534383A |
Compounds and methods are provided for the preparation of a red blood cell composition which has significantly reduced antigenicity and in which any possible pathogen contaminants have been substantially inactivated. The red blood cell c...
|
|
JP2003534234A |
The invention relates to an active ingredient matrix in the form of a biologically resorbable porous non-woven made of collagen fibrils in a dry frozen state with delayed release of said active ingredients. The matrix contains at least o...
|
|
JP2003534277A |
The invention relates to a method of treating, and improving survival in, critically ill patients, and the use of certain sterile sedative pharmaceutical compositions for the manufacture of a medicament for improving the survival of such...
|
|
JP2003533450A |
Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
|
|
JP2003533521A |
The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certai...
|
|
JP2003532383A |
The present invention relates to novel human human polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods ...
|
|
JP2003532725A |
Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described.
|
|
JP2003532691A |
This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level.
|
|
JP2003532684A |
The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.
|
|
JP2003531590A |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
JP2003531590A5 |
|
|
JP2003530839A |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
JP2003300977A |
To obtain a compound with high DPP-IV inhibitory activity or improved safety, toxicity, etc.The xanthine derivative is represented by formula [ring E is a six-membered or seven-membered hydrocarbon ring or a six-membered or seven-membere...
|
|
JP2003530846A |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
JP2003530852A |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
JP2003530838A |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
JP2003530847A |
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...
|
|
JP2003530315A |
The use of scopolamine salts for preventing the onset of epilepsy that might ensue after the condition of status epileticus, major head trauma, including those occasioned by neurosurgical trauma, and acute lesional events to the brain.
|
|
JP3454836B2 |
PURPOSE: To obtain an external powdery agent for the treatment of dermatic diseases, containing a cyclic AMP derivative, effective for stably keeping the derivative and capable of controlling the release of the derivative by using a wate...
|
|
JP2003528833A |
A method of stabilizing kidney function in transplant patients is disclosed. In one embodiment, the method comprises the steps of kidney transplant patient, wherein the transplant patient is undergoing immunosuppressive therapy, with a s...
|
|
JP2003267888A |
To provide a cardiac arrest fluid mitigating a damage on the myocardium and having excellent cardiac function-retaining effect.The cardiac arrest fluid contains a poly-ADP ribose synthetase inhibitor and metal ions such as Na+, K+, Mg++ ...
|
|
JP2003528097A |
The present application describes novel beta-amino acid derivatives of formula I:or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specificat...
|
|
JP2003527844A |
Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been iden...
|
|
JP2003261545A |
To provide a neurotrophic factor production/secretion accelerator having excellent activity and low toxicity.The neurotrophic factor production/secretion accelerator contains a compound expressed by general formula (I) [one of R1 and R2 ...
|
|
JP2003527432A |
The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use o...
|
|
JP2003527426A |
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and are selected from the group consisting of:or a pharmaceutically acceptable salt thereof, whereinA is
|
|
JP2003526371A |
A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid sequences as defined, for use in the treatmen...
|
|
JP2003525942A |
A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothi...
|
|
JP2003525900A |
The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an inhibitor of the Tec family of protein tyrosine kinases (PTKs). The condition is typically associated wi...
|
|
JP2003525224A |
A pharmaceutical preparation containing zaleplon (I) consists of a transdermal therapeutic system (TTS) in plaster form, comprising a backing layer, a (I)-containing pressure sensitive reservoir is bonded to the backing layer and a prote...
|
|
JP2003525243A |
Topoisomerase inhibitors are useful for the treatment of inflammatory disorders including arthritis, restonosis, surgical adhesions and other diseases. Controlled release polymeric formulations to topoisomerase inhibitors are particularl...
|
|
JP2003523339A |
A beta-alanine derivative of the formula (I) wherein R<1 >is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R<2 >is hydrogen atom or an amino group which may be substituted with an ac...
|
|
JP2003522751A |
Aromatic dehydroamino acids are disclosed that are active as LFA-1 arnagonists This activity enables these compounds to prevent inflammation which is a consequence of T cell activation and accordingly reduce or eliminate inflammatory ski...
|
|
JP2003522191A |
The invention provides certain pyrimidine compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy. Formula (I) in which: A is a group of formula (a), (b) or (c).
|
|
JP2003521903A |
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid se...
|
|
JP2003522189A |
The invention provides certain heterocyclic compounds, processes, and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).
|
|
JP2003522325A |
Disclosed is a compound which inhibits binding between a target protein and a macromolecular ligand of the target protein. The compound comprises a targeting group, an attaching group and, optionally a linker group. In one aspect of the ...
|
|
JP2003521467A |
This invention is related to a method whereby scar formation in the drainage fistula and subconjunctival bleb created during and after glaucoma surgery using a prostaglandin subtype A or J.
|
|
JP2003521247A |
The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a protein tyrosine phosphatase (PTP), e.g., PTPL1. The present invention provides methods for screening a PTPL1 agonist or antag...
|
|
JP2003521251A |
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CUB domain polypeptide. These polynucleotides comprise nucleic acid s...
|
|
JP2003192659A |
To provide a drug containing a phenylnaphthylurea derivative or a salt thereof as an active ingredient.This drug contains a compound of general formula (I) {e.g. N-(3,4-dichlorophenyl)-N'-[2-(2-hydroxyethyl)phenyl]urea} as the active ing...
|
|
JP2003192597A |
To provide an adhesion preventive agent that can prevent postoperative tissues from being mutually adhered.The adhesion preventive agent includes sodium carboxymethylcellulose (Na CMC) and gellan gum at a weight ratio of 1:(0.1-10). This...
|
|
JP3420851B2 |
PURPOSE: To obtain the subject preventing agent, constituted of a crosslinked hyaluronic acid having mutually crosslinked carboxyl groups, insolubilized in water, retainable in tissuey lesions for a desired period and capable of sustaini...
|
|
JP2003519680A |
This invention s directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds having the following structure:wherein A, B, R, R1, p and q are as defined herein. The invention s all directed to pharmaceutical compositions conta...
|
|
JP2003518940A |
The invention relates to nucleic acid molecules encoding chemotaxis inhibitory (poly)peptides, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for prepari...
|
|
JP2003518069A |
Pharmaceutical composition for the prophylactic treatment of secondary injury of tissue, said secondary injury being induced by primary injury of mainly surrounding tissue and being the result of a traumatic event, wherein the pharmaceut...
|
|
JP2003518190A |
An adhesive composition that contains cyanoacrylate monomers and cyclic or alkyl- or phenyl-terminated linear polydimethylsiloxane is particularly useful in applications requiring flexibility and elasticity.
|
|
JP2003517477A |
There are disclosed compounds of formula (I)and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.
|
|
JP2003516927A |
The invention described herein relates to the discovery of methods and compositions for the inhibition of growth and/or migration of cells that have the P antigen, including but not limited to, cells of hematopoietic origin and endotheli...
|
|
JP2003137783A |
To obtain a new compound having 3 kinds of functions comprising the functions of free radical scavenger (antioxidation agent), AGE inhibitor and AGE breaker, more particularly, provide a composition and method for the use of a pyridinium...
|
